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n Abstract: Pregnancy-related breast cancer (PBC) is one of the most common malignancies during pregnancy
(approx. one in 3,000 pregnancies); up to 3% of breast cancers are diagnosed in pregnancy. As maternal age at the time
of pregnancy continues to increase as the incidence of breast cancer, the incidence of PBC is expected to increase. A
review of the literature was performed in order to identify optimal treatment strategies. Most of the data surrounding the
diagnosis and treatment PBC is small cohort studies, and there are no randomized controlled trials. Diagnostic delays are
common. Preoperative histologic confirmation is required. Conservative surgery can be proposed at the end of second and
third trimester, and radiotherapy is delayed after childbirth. The safety of sentinel lymphnode biopsy has yet to be con-
firmed, and the axillary dissection is the traditional treatment of choice. The chemotherapeutic agents utilized are the same
as those used in non-pregnant patients, but they should not be administered in the first trimester. Radiotherapy and endo-
crine therapy are recommended to be avoided during pregnancy. The treatment of PBC is multidisciplinary and necessitates
active communication among the patient, obstetrician, medical, surgical, and radiation oncologists. Diagnosis is often
delayed because of physiologic changes of the breast; obstetricians should perform a thorough breast examination at the
first prenatal visit and maintain a high index of suspicion for cancer. Other therapies may need to be considered, although
their usage now is not currently recommended owing to the paucity of safety data. n
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Pregnancy-related breast cancer (PBC) represents3% of all breast cancers with an incidence of
10–40 per 100,000 pregnancies; it is the second most
common cancer occurring during pregnancy secondary
only to cervical cancer.
Because nowadays it is a current trend to delay
childbearing until the late fertile age, PBC rate is
expected to increase. PBC is becoming a more fre-
quent problem faced by a multidisciplinary team com-
posed by surgeons, oncologists, gynecologists, and
obstetricians.
Because of its low incidence similarly to other can-
cer arising during pregnancy, it is difficult to conduct
large prospective studies on PBC in order to examine
diagnostic and therapeutic tools and options; no evi-
dence exists concerning the management of this patho-
logical condition.
DIAGNOSIS
A controversial issue in PBC is the delay in diagno-
sis; most recent studies report a delay in diagnosis of
1–2 months (1–3). Therefore, PBC often presents as
locally advanced disease. During pregnancy, breasts
are involved in severe morphologic changes. There is a
marked increase in number and complexity of the ter-
minal ductules resulting in physiologic hyperplasia of
the terminal duct and lobular units. In term preg-
nancy, the ductules are transformed into complex
structures with hyperplastic lining cells showing evi-
dence of secretory activity and papillary infolding. In
the later stages of pregnancy, there is loss of staining
of the terminal duct epithelial cells for estrogen and
progesterone receptor protein.
Clinical examination of breasts during pregnancy is
difficult because breast presents increased density and
firmness. About 80% of women with a palpable pain-
less lump during pregnancy have a benign mass. Any
palpable lump persisting for more than 2 weeks
should be deeper investigated with further specific
workup. Nipple discharge and ‘‘milk rejection’’ sign
are not frequently present.
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When a breast nodule is clinically detected during
pregnancy, the first examination to be performed is
ultrasound examination, which is a safe and accurate
imaging technique. Moreover, ultrasound examina-
tion is also useful to perform fine-needle aspiration or
core biopsy that is necessary to reach a definitive
diagnosis.
Owing to physiologic changes occurring in breasts
during pregnancy, mammography has less sensitivity
and is associated with a high false-negative rate; any-
way it remains a fundamental imaging tool in the
evaluation of PBC. Mammography exposes fetus only
to 0.004 Gy, below the threshold for deterministic
effect (4).
The use of breast magnetic resonance imaging
(MRI) is still controversial because the challenging to
discriminate malignant and physiologic hypervascular-
ization occurring during pregnancy and because gado-
linium crosses the placenta and is associated with fetal
abnormalities in rats (5).
In the diagnostic process, fine-needle aspiration
biopsy (FNAB) remains an increasingly important
diagnostic tool in the assessment of the nature of
various breast lesions. During pregnancy, FNAB pro-
vides an opportunity for women to have their breast
lesions sampled and examined without significant
morbidity for patient and her fetus. The established
diagnosis of breast cancer by FNAB allows more
flexibility for treatment planning providing prognos-
tic information (6,7). As PBC often occurs as a
large mass, core biopsy could be indicated. More-
over, core biopsy could be performed when FNAB
is not successful. In rare cases, core biopsy may
cause a milk fistula, so it is important to accurately
empty the breast with ice packs and binding before
biopsy.
When breast cancer is demonstrated, an accurate
staging of the disease is needed. Chest X-ray is a safe
procedure exposing the fetus at 0.0001 Gy; ultrasound
is accurate in evaluating hepatic and abdominal condi-
tions and low-dose bone scan could be used for bone
metastases, although no overall consensus among
authors has been obtained for this last examination.
Unenhanced MRI could be performed in case of sus-
pected liver or bone metastases (8–11).
PATHOLOGY
In about 80% of patients, PBC is an infiltrating
ductal carcinoma. The majority of breast cancers in
pregnancy present high grade and lymphovascular
invasion. Microscopically PBC shows high cell yield
with granular proteinaceous background; often dis-
persed cells and loosely arranged cell clusters, large
epithelial cells with uniform nuclei and prominent
nucleoli; abundant, foamy, vacuolated cytoplasm with
fraying of cytoplasmic borders. Many studies showed
that around 70% of these tumors are estrogen and
progesterone receptors negative in contrast to non-
pregnant women (2,3). About two-thirds of cases at
diagnosis show a lymphnodal involvement. Studies
with limited population also revealed a higher expres-
sion of Her2 ⁄neu (12,13).
TREATMENT
The treatment of PBC is a challenging issue because
of the lack of standardized guidelines and evidences
arising from randomized controlled trials. Planning
and timing of different therapeutic procedures is
strictly related to the stage of the tumor and to the
health of fetus and the mother. The need for prompt
treatment presents a clinical dilemma of considerable
magnitude as there is always a conflict between opti-
mal maternal therapy and the resultant risks imposed
on fetal well-being.
However, the goal for treatment of the pregnant
woman with breast cancer is the same as that of the
nonpregnant patients with breast cancer: local control
of the disease and prevention of systemic metastases.
During pregnancy, some treatment modalities need to
be modified because of the potential for adverse
effects on the fetus.
Surgery
Surgery remains the mainstay of treatment of breast
cancer during pregnancy and is the first step of a mul-
tidisciplinary approach to the tumor as in nonpreg-
nant patients. Surgery is a safe procedure; it can be
performed in all trimesters of pregnancy with minimal
risk for the fetus; after the 12th week of gestation, the
risk of abortion is minimal (8–11).
Mastectomy and axillary lymphadenectomy are the
surgical procedures most frequently performed
because of the large size of the tumor at presentation
and the higher rate of axillary nodal involvement.
Radical mastectomy can be followed by immediate
breast reconstruction with implants and also in preg-
nant women this is considered an effective step of the
treatment of breast cancer.
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Breast-conserving surgery could be performed pref-
erably in the last trimester because of the necessity to
be followed by radiotherapy that in any case must be
delayed after surgery. Moreover, after the first trimes-
ter it is possible for the patients to undergo chemo-
therapy before or after surgery.
Sentinel lymphnode biopsy in pregnant women is
little evaluated, and there is not overall consensus
among Authors in literature on the safety of this pro-
cedure during pregnancy owing to radiation concerns.
Gentilini et al. recently showed the results of a study
conducted on 12 pregnant women with breast cancer
who received low-dose lymphoscintigraphy using
99m-Tc human serum albumin nanocolloids; eleven
healthy babies were born with no malformation, one
baby had a ventricular septal defect suspected before
the lymphoscintigraphy was performed. They support
the safety of sentinel lymphnode biopsy in pregnant
patients with breast cancer (14).
Radiotherapy
Radiation therapy is contraindicated during preg-
nancy owing to its teratogenic effects on fetus. In the
first trimester (before the completion of organogene-
sis), radiotherapy may be related to fetal death, mal-
formations, mental retardation, and induction of
childhood neoplasms and hematologic disorders (15).
Chemotherapy
As PBC often presents as locally advanced disease
at diagnosis, chemotherapy could be proposed as adju-
vant or neoadjuvant treatment. There are few pub-
lished data concerning the use of chemotherapy for
breast cancer during pregnancy. The risk of major
complications using cytotoxic agents is related to the
time of application, type of agent, and variations of
factors such as plasma volume, hepatorenal function,
or albumin concentration. In the first trimester, the risk
of congenital malformations ranges from 10–20%,
whereas it drops to 1.3% in the third trimester (16).
Chemotherapy is generally not administered during the
first trimester because of the possible damage to organ-
ogenesis, whereas during the second and third trimes-
ters has lower complications. A large retrospective
multicenter series from five London Teaching Hospitals
reported no major fetal malformations in 27 children
whose mothers were treated with chemotherapy regi-
mens based on cyclophosphamide, metothrexate, fluo-
rouracil and anthracycline at second and third trimester
(17), providing evidence that in terms of peripartum
complications and immediate fetal outcome, chemo-
therapy can be safely administered (with same efficacy)
to women during the last two trimesters of pregnancy.
Similarly, a group of oncologists from the Univer-
sity of Texas M.D. Anderson Cancer Center reported
in a series of 57 patients treated with fluorouracil,
doxorubicin, and cyclophosphamide chemotherapy
no significant short-term complications to the fetus
(18).
Hormonal therapy
As pregnancy-associated breast tumors are usually
poor in estrogen receptor, they are believed to be
unresponsive to hormonal therapy. There are also few
data about the use of anti-hormonal therapy during
pregnancy and nowadays it is not recommended (19).
There are some reports that describe neonatal abnor-
malities of the genital tract (20). Although no fetal
abnormalities are reported in the study of Clark (21)
on 85 women who took tamoxifen for breast carci-
noma prevention, further confirmations have to be
obtained before proposing clinical use of hormonal
therapy during pregnancy.
Termination of pregnancy
Termination of pregnancy and postpartum delayed
treatment are not routinely recommended in the case
of PBC and a number of reported series suggested
that it does not improve survival (22). In case of
advanced disease presented in the first trimester,
abortion can be proposed to avoid delay in treat-
ment.
CONCLUSIONS
Pregnancy-related breast cancer is still a controver-
sial issue. Diagnosis of PBC may be difficult owing
to the physiologic modifications of the breast struc-
ture during pregnancy. Treatment of PBC is challeng-
ing in consideration of the potential risks for the
fetus and the possible maternal benefit. Given its dif-
ferent and various implications, biologic, diagnostic,
therapeutic, and psychologic, the management of
PBC needs a multidisciplinary cooperating team; a
close cooperation between all disciplines is manda-
tory in order to reach an optimal treatment strategy
for the patient and her unborn child. Future evidence
and ongoing studies are expected to solve problems
related to breast cancer management during preg-
nancy.
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